论著

眼内压测定评估长期使用鼻用激素患者的眼部安全性

展开
  • a.上海交通大学医学院附属瑞金医院 耳鼻喉科,上海 200025
    b.上海交通大学医学院附属瑞金医院 眼科,上海 200025

收稿日期: 2019-03-27

  网络出版日期: 2019-08-25

Value of intraocular pressure for assessment of ocular safety of intranasal steroids

Expand
  • a. Department of Otorhinolaryngology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
    b. Department of Ophthalmology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Received date: 2019-03-27

  Online published: 2019-08-25

摘要

目的: 由于长期使用鼻用激素可能会引起各种不良反应,其中包括导致患者眼内压(intraocular pressure,IOP)升高。本研究通过观察2种临床常用鼻用激素(包括第一代和第二代鼻用激素)使用后患者的IOP变化情况,探讨IOP测定在长期使用鼻用激素患者眼部安全性评估中的重要价值。方法: 将52例变应性鼻炎患者随机分为2组,分别使用第一代和第二代鼻用激素进行治疗,为时12周。在治疗前及治疗后3周、6周、9周、12周分别测量患者的IOP,分别对2组内治疗前和治疗后各时期的IOP进行比较。结果: 使用第一代鼻用激素治疗组,治疗后3周、6周、9周时患者的IOP与治疗前比较,略有缓慢升高的趋势,但差异尚无统计学意义(P>0.05);而在治疗后12周,患者的IOP则明显高于治疗前,差异有统计学意义(P=0.02)。而使用第二代鼻用激素治疗组,治疗后各时期的IOP与治疗前比较,差异均无统计学意义(P>0.05)。结论: 对于长期使用鼻用激素,尤其是第一代鼻用激素的人群,随访监测IOP可以作为评估其眼部安全性的重要指标。

本文引用格式

吴继昌, 何刚迅, 施知泓, 陈燕 . 眼内压测定评估长期使用鼻用激素患者的眼部安全性[J]. 诊断学理论与实践, 2019 , 18(04) : 466 -469 . DOI: 10.16150/j.1671-2870.2019.04.016

Abstract

Objective: Many side effects including elevation of intraocular pressure (IOP) due to long-term use of intranasal steroids were reported, especially with the first generation intranasal steroids, yet the second generation intranasal steroids were believed only having a minimal impact on IOP because of low bioavailability. The object of this study was to assess the value of IOP for assessing the ocular safety of two intranasal steroids (the first generation and the second generation) for treatment of 12-week period. Methods: Fifty two allergic rhinitis patients were divided randomly into two groups using either the first or second generation intranasal steroids for 12 weeks, respectively. IOPs were measured before treatment and after the 3rd, 6th, 9th, and 12th weeks of treatment. The IOPs of the two groups were compared. Results: The IOP of the first-generation intranasal steroids at 3, 6 and 9 weeks after treatment were not statistically different from those before treatment, while the IOP at 12 weeks after treatment were statistically different from those before treatment. Meanwhile, there were no statistically significant differences between the IOP at various stages of treatment and that before treatment with the use of second generation intranasal steroids. Conclusions: For patient with long standing use of nasal steroids, IOP could be considered as an important index for assessing the ocular safety.

参考文献

[1] LaForce C, Journeay GE, Miller SD, et al. Ocular safety of fluticasone furoate nasal spray in patients with perennial allergic rhinitis: a 2-year study[J]. Ann Allergy Asthma Immunol, 2013, 111(1):45-50.
[2] Liu A, Manche EE. Bilateral posterior subcapsular cataracts associated with long-term intranasal steroid use[J]. J Cataract Refract Surg, 2011, 37(8):1555-1558.
[3] Opatowsky I, Feldman RM, Gross R, et al. Intraocular pressure elevation associated with inhalation and nasal corticosteroids[J]. Ophthalmology, 1995, 102(2):177-179.
[4] 葛坚. 眼科学[M]. 北京: 人民卫生出版社, 2002:50.
[5] Kersey JP, Broadway DC. Corticosteroid-induced glaucoma: a review of the literature[J]. Eye (Lond), 2006, 20(4):407-416.
[6] Bross-Soriano D, Hanenberg-Milver C, Schimelmitz-Idi J, et al. Effects of three nasal topical steroids in the intraocular pressure compartment[J]. Otolaryngol Head Neck Surg, 2004, 130(2):187-191.
[7] Bergmann J, Witmer MT, Slonim CB. The relationship of intranasal steroids to intraocular pressure[J]. Curr Allergy Asthma Rep, 2009, 9(4):311-315.
[8] Garbe E, LeLorier J, Boivin JF, et al. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma[J]. JAMA, 1997, 277(9):722-727.
[9] Oztürk F, Yücetürk AV, Kurt E, et al. Evaluation of intraocular pressure and cataract formation following the long-term use of nasal corticosteroids[J]. Ear Nose Throat J, 1998, 77(10):846-848,850-851.
[10] Bui CM, Chen H, Shyr Y, et al. Discontinuing nasal steroids might lower intraocular pressure in glaucoma[J]. J Allergy Clin Immunol, 2005, 116(5):1042-1047.
[11] Spiliotopoulos C, Mastronikolis NS, Petropoulos IK, et al. The effect of nasal steroid administration on intraocular pressure[J]. Ear Nose Throat J, 2007, 86(7):394-395.
[12] Bousquet J, van Cauwenberge P, Khaltaev N, et al. Allergic rhinitis and its impact on asthma[J]. J Allergy Clin Immunol, 2001, 108(5 Suppl):S147-S334.
[13] Clark AF, Wilson K, McCartney MD, et al. Glucocorticoid-induced formation of cross-linked actin networks in cultured human trabecular meshwork cells[J]. Invest Ophthalmol Vis Sci, 1994, 35(1):281-294.
[14] Benninger MS, Ahmad N, Marple BF. The safety of intranasal steroids[J]. Otolaryngol Head Neck Surg, 2003, 129(6):739-750.
[15] Yuen D, Buys YM, Jin YP, et al. Effect of beclomethasone nasal spray on intraocular pressure in ocular hypertension or controlled glaucoma[J]. J Glaucoma, 2013, 22(2):84-87.
[16] Dreyer EB. Inhaled steroid use and glaucoma[J]. N Engl J Med, 1993, 329(24):1822.
[17] Man LX, Farhood Z, Luong A, et al. The effect of intranasal fluticasone propionate irrigations on salivary cortisol, intraocular pressure, and posterior subcapsular cataracts in postsurgical chronic rhinosinusitis patients[J]. Int Forum Allergy Rhinol, 2013, 3(12):953-957.
[18] Spiliotopoulos C, Mastronikolis NS, Petropoulos IK, et al. The effect of nasal steroid administration on intraocular pressure[J]. Ear Nose Throat J, 2007, 86(7):394-395.
文章导航

/